Midas.inrf.uci.edu

metoclopramide was given only if the PONV symptoms per- sisted for 15 min or longer after treatment was initiated. A blinded observer recorded the recovery times, emetic symp- toms, rescue antiemetics, maximum nausea scores, completeresponse to study treatment, and time to achieve discharge criteria. Postdischarge side effects, as well and patient sat- Margarita Coloma, Paul F. White, Babatunde O. Ogunnaike, isfaction and quality of recovery scores, were assessed at Scott D. Markowitz, Philip M. Brown, Alex Q. Lee, 24 and 72 hr after surgery. The combination group had a Sally B. Berrisford, Cynthia A. Wakefield, Tijani Issioui, markedly greater complete response rate than the acustimu- lation group (73% vs. 40%), In addition, fewer patients (8 vs.
18) in the combination vs. the acustimulation group expe- rienced subsequent antiemetic events. However, there wereno marked differences between the three groups in patient Departments of Anesthesiology and Pain Management Surgery, University satisfaction and quality of recovery scores. Acustimulation of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
with the ReliefBand1 can be used as an alternative to on- n 2003 by Lippincott Williams & Wilkins dansetron for the treatment of established PONV. However,the use of ondansetron (4 mg intravenously) in combinationwith the ReliefBand1 device improved the complete response Transcutaneous electrical acupoint stimulation (acustimu- rate totheacustimulation therapy.
lation) was evaluated using the ReliefBand1 compared with ondansetron for the treatment of established postoper- ative nausea and vomiting (PONV) after outpatient laparo- It is possible to identify those at high risk for post- scopic surgery. With institutional review board approval and operative nausea and vomiting (PONV) and to provide written informed consent, 268 outpatients were enrolled in antiemetic prophylaxis to these patients. This paper is a randomized, double-blind, placebo- and sham-controlled concerned with how to treat high risk patients who fail this study. All patients were given antiemetic prophylaxis with approach and have PONV despite treatment in the operating metoclopramide, 10 mg intravenously, or droperidol, 0.625 mg room. The finding that PONV outcome in those patients intravenously, after induction of anesthesia. A total of 90 pa- treated with the acustimulation band was not significantly tients developed PONV in the recovery units and were ran- different from those treated with ondansetron is interesting.
domized to one of three treatment groups: (1) the ondansetron That the combination of the acustimulation band and ondan- group received 4 mg of intravenous ondansetron and a sham setron produced superior results compared to the band alone ReliefBand1; (2) the acustimulation group received 2 mL of suggests that the band may have a role in a multimodal intravenous saline and a ReliefBand;1 and (3) the combi- nation group received 4 mg of intravenous ondansetron anda ReliefBand.1 A rescue antiemetic of 10 mg intravenous Survey of Anesthesiology  Volume 47, Number 5, October 2003 Copyright ' Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Source: http://midas.inrf.uci.edu/groups/bats/uploads/Electrodes/Coloma_AmbulAnesth_2003.pdf

Chapter 22 e-health 2.0 developments in treatment and research in multiple sclerosis

E-Health 2.0 Developments in Treatment and Research in Multiple Sclerosis The MS4 Research Institute (MS4RI) 1. Introduction The treatment of multiple sclerosis (MS) is entering a new era, characterized by the availability of a broad range of disease modifying drugs (DMDs) for patients in the relapsing-remitting (RR) phase of the disease. Through interference with immune-mediated in

diagnosidipendenze.eu

Easy PDF Copyright © 1998,2007 Visage Software UN'ESPERIENZA DI APPROCCIO INTEGRATO AL PAZIENTE COCAINOMANE Diagnosi e terapia all'interno del Centro Diurno " Stella Polare " Stefania Sciortino, Psicologa clinica presso il Centro Diurno “Stella Polare”, ASL Via Adolfo Scalpelli, 1 – 00019 Tivoli (RM) – tel. 0774/314815 - cell.3476046374 Simone De Persis, Med

© 2010-2018 PDF pharmacy articles